Systemic Lupus Erythematosus and Hereditary Coproporphyria: Two Different Entities Diagnosed by WES in the Same Patient

Anlei Liu, Lingli Zhou, Huadong Zhu, Yi Li, and Jing Yang

Emergency Department, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China

Correspondence should be addressed to Jing Yang; yangbujing@126.com

Received 22 March 2022; Revised 27 April 2022; Accepted 16 May 2022; Published 28 May 2022

1. Introduction

Hereditary coproporphyria (HCP) is a kind of acute hepatic porphyria (AHP) and a rare autosomal dominant disorder caused by genetic mutation in coproporphyrinogen III oxidase (CPOX) [1]. Patients with HCP can present with serious abdominal, psychiatric, neurologic, cardiovascular, or cutaneous symptoms [1]. Systemic lupus erythematosus (SLE) is an autoimmune disorder in which autoantibodies that damage multiple organs are produced [2]. Genetic predisposition plays an important role in SLE etiology [3]. Over thirty genes were reported to be related to monogenic lupus disease or lupus-like diseases, including SLC7A7 (solute carrier family 7 member 7 gene) [4–6]. The coexistence of AHP and SLE is extremely rare [7–10]. We reported a difficult diagnosis of HCP in a patient with a six-year history of SLE, in which HCP was caused by a novel CPOX variant and SLE might have been related to the SLC7A7 variant background.

2. Materials and Methods

2.1. Case Report. A 30-year-old woman with SLE was admitted to the emergency department because of abdominal pain.
On September 15, 2020, she developed a sore throat and cough and was subsequently treated with roxithromycin, ambroxol, and Honghua (a kind of Chinese traditional medicine). On September 17, acute and severe abdominal pain and cramping developed, with concomitant left low back pain, vomiting, and dysuria but no venting or defecation. She presented to a local hospital, where a clinical diagnosis of intestinal obstruction was made and fasting, gastric intubation, and support treatments were prescribed. The patient felt no release of abdominal pain and was transferred to the emergency department of this hospital on September 22. She had a background of pulmonary tuberculosis twenty years ago and was treated with isoniazid and rifampicin for two years. The patient was diagnosed with immune thrombocytopenia (ITP) in 2002, she suffered from frequent hemorrhage for ten years and finally underwent splenectomy in 2012, and she presented with an itchy rash on her face and limbs after exposure to sunlight in 2014. Autoantibody testing showed that antinuclear antibody (ANA) was elevated (1:640); Sm, SSA, RO 52, and Scl 70 antibodies were positive, while double-stranded DNA (ds-DNA) antibodies were negative. No other organ involvement was noticed. She was diagnosed with SLE and administered hydroxychloroquine (HCQ, 0.4 g/d) and prednisone (7.5 mg/d). Her last menstruation began on September 20, exactly the third day after abdominal pain developed. She denied any alcohol, tobacco, or drug abuse. Her family history was significant for lung cancer (mother died of lung cancer).

On admission, oral examination revealed oral mucosal dryness and bleeding and several lower lip mucosa ulcers. The abdomen was soft, with decreased bowel sounds, and tenderness was noticed around the bellybutton. Laboratory studies revealed hyponatremia (128 mmol/L) and increased C-reactive protein (14.07 mg/L). Liver enzymes, bilirubin, albumin, creatinine, uric acid, glucose, cholesterol, serum amylase and lipase, thyroid tests, erythrocyte sedimentation rate, and complement (C3 and C4) tests were normal. Antinuclear antibody (ANA) levels were elevated (1:160), SSA 60 and RO 52 antibodies were positive, and double-stranded DNA (ds-DNA) and other nuclear antigen antibodies were negative. Electrocardiogram showed sinus tachycardia. Abdominal and pelvic CT scans revealed a soft tissue signal behind the uterus and a suspicious small stone at the pelvic part of the ureter. Trimadol and chlorpromazine were administered to control the abdominal and back pain. Therapy was initiated with ertapenem (1 g/d) and methylprednisolone (0.5 mg/kg body weight) because of the infection, and the medication prescribed for SLE was suspended because of the sudden onset of symptoms. Oral laxative and intravenous infusion of 10% glucose and saline were administered due to suspicious intestinal obstruction.

The patient presented with worsening weakness and dysuria after 24 hours of admission. Reddish urine was noticed after indwelling a urinary catheter. This finding raised the suspicion of acute porphyria. The urine turned a dark brown color after one hour of exposure to sunlight (Figure 1). The urobilinogen level was 33 μmol/L (reference range, 3 to 16 μmol/L), and the uroporphyrinogen (UPG) and porphobilinogen (PBG) tests were positive. Free erythrocyte protoporphyrin (FEP) was 5.3 μg/gHb (reference range, 0 to 4.7 μg/gHb). Brain magnetic resonance imaging did not reveal any pathologic features.

Based on these findings, we made a tentative diagnosis of acute porphyria. Ertapenem and methylprednisolone were stopped as the neutrophil levels returned to normal. Sufficient glucose support (250-300 g/d), restriction of liquids (<2500 mL/d), and moderate sodium supplements were administered. Morphine (5 mg) was given to relieve pain when necessary. Hydroxychloroquine (0.4 g/d) and prednisone (7.5 mg/d) were restarted for SLE. Within a four-month follow-up, no abdominal symptoms were observed.

Based on these findings, we decided to examine the genetic causes of the disease in her family.

2.2. Molecular Analysis. Total DNA was extracted from peripheral blood leukocytes of the patient and her father using standard methods. Whole exome sequencing (WES) was performed using Gencap™ Human whole Exon Probe V4.0 (Myogenetics, Beijing, China), and exome libraries were sequenced using the GenCap™ Platform (Myogenetics, Beijing, China). Sanger sequencing was used to confirm the variants.

2.3. Data Analysis and Variant Interpretation. Sequence reads were aligned to the February 2009 human reference sequence (GRCh37/hg19) assembly. Protein function was predicted by the rare exome variant ensemble learner (REVEL). Pathogenicity analysis of the mutation was performed in the Clinically Relevant Variants (ClinVar) database. Variants were numbered according to the Human Genome Variation Society (HGVS) recommendations for variant nomenclature (https://www.HGVS.org/varnomen).

2.4. Microarray Data Resource. A gene expression profile dataset (GSE51997) based on data obtained from the Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo/) was produced on the GPL570 Affymetrix Human Genome U133 Plus 2.0 Array. According to the annotation information in the platform, the probes were alternated with corresponding gene symbols. GSE51997 contains eight CD16 inflammatory monocytes from normal specimens and four CD16 inflammatory monocytes from active SLE specimens.

2.5. Identification of DEGs. The online tool GEO2R (http://www.ncbi.nlm.nih.gov/geo/geo2r) was applied to screen differentially expressed genes (DEGs). GEO2R is an intelligent web device that empowers clients to compare at least two datasets in a GEO series to distinguish DEGs. The adjusted P values (adj. P) and Benjamini and Hochberg false discovery rates were generated to ensure consistency among methods used to measure large quantities of data and control the false-positive rate.

3. Results

3.1. Molecular Analysis. A novel CPOX gene (NM_000097) heterozygous mutation, c.700+2T>C (intron 2), was detected by WES and confirmed by Sanger sequencing in
the proband, which led to a splicing mutation (Figure 2). The diagnosis of HCP was determined in the proband. This variant is absent in public population genomic databases, and the protein function of this variant was predicted to be unknown. According to American College of Medical Genetics (ACMG) variant interpretation guidelines, the variant is preliminarily considered likely pathogenic (PSV1+PM2).

Sanger sequencing was used to detect the CPOX fragment of the proband’s family members. The same mutation was not detected in her father. No genetic data of the patient’s mother were obtained because she died from lung cancer ten years ago. No similar rash, abdominal pain, or elevated liver enzymes were noticed in her mother.

WES also identified 62 other gene variants, from which only SLC7A7 has been reported to be associated with monogenic lupus disease. WES showed compound heterozygous variants in SLC7A7 (NM_001126106): c.250G>A (p.V84I) in exon 3 and c.625+1G>A (splicing) in intron 4.

3.2. Data Quality Assessment and Identification of DEGs. Heatmap and unsupervised clustering analyses were performed to reveal the distribution of gene expression data in GSE51997 (Figure 3). DEGs were detected from GSE51997 by GEO2R (adj. \( P < 0.01 \), \( \mid \log FC \mid > 1 \)). The expression of CPOX was downregulated in SLE patients compared with normal controls (adj. \( P = 0.0071 \), \( \log FC = -1.0975 \)).

4. Discussion

Acute hepatic porphyria (AHP) is differentiated into four types: acute intermittent porphyria (AIP), variegate porphyria (VP), hereditary coproporphyria (HCP), and amino-laelulinic acid dehydratase-deficient porphyria (ALADP). The main data of the 15 reported cases showing the coexistence of AHP and SLE, including the present case, are summarized in Table 1. AIP, the most common type of AHP, was reported to coexist with SLE in twelve cases [7, 8, 11–15]. Genetic defects, metabolic defects, and acquired autoimmune phenomena have been proposed to explain the coexistence of these two diseases [7–10]. Latent AIP might become clinically active by the pathological process of SLE or SLE treatment [8]. Rifampicin is porphyrinogenic, and HCQ is possibly porphyrinogenic [7, 16]. An overview of the patient’s medication showed that the above drugs were not likely to represent direct triggers responsible for this attack. Meanwhile, there was no sign of SLE activity. This attack might have been triggered by upper respiratory tract infection and menstruation.

As porphyria can mimic symptoms and signs of other common disorders, a high frequency of misdiagnosis or delayed diagnosis is observed [1, 9, 17]. However, porphyrias can be easily defined and diagnosed according to the overproduction of porphyrin precursors [1]. Several puzzling points hindered early diagnosis of this case. The patient...
had a medical history of SLE and splenectomy and suffered severe abdominal pain immediately after an infection. In addition, an abnormal soft tissue signal behind the uterus and several small ureteral calculi were shown on CT. SLE-related intestinal pseudoobstruction and postoperative adhesive intestinal obstruction were considered first, and pelvic neoplasm and ureteral calculi were also taken into account. The keys to the diagnosis of porphyria were reddish dark urine, positive UPG and PBG, and increased FEP. The symptoms developed in this patient, including abdominal pain, vomiting, dysuria, tachycardia, hypertension, and hyponatremia, could all be explained by an attack of AHP. Finally, the diagnosis of HCP was confirmed by a CPOX mutation identified by WES.

HCP is the rarest of the autosomal dominant AHFs and is characterized by a deficiency of CPOX, the sixth enzyme in the heme biosynthetic pathway. HCP has over 50 reported mutations that lead to variations in penetrance and phenotype [1]. We detected a novel CPOX heterozygous mutation in the proband: c.700+2 T \( \rightarrow \) C (intron 2). This variant caused a splicing mutation, and a part of intron 2 could be expressed following exon 2, which may result in a loss of gene function. The patient presented with serious abdominal, psychiatric, and cardiovascular symptoms but no cutaneous symptoms. Her father did not carry the same mutation, and the genetic background of her mother was lacking. Although HCP is inherited in an autosomal dominant manner, the proband’s mother did not have a history of symptoms similar to those of HCP. We could not determine whether the mutation originated in the proband or was inherited from her mother. Acute porphyria has low penetrance, and approximately 90% of affected individuals never experience an acute attack [18]. The allele frequency distribution of missense, nonsense, and splice-site variants is also different in various ethnic and demographic populations for porphyrias [19]. Lambie et al. [17] reported a novel missense mutation of HCP with 100% penetrance in a family. Fukui et al. [20] reported a case of HCP with a homozygote missense mutation presenting with a mild clinical phenotype. The novel CPOX variant in our patient may be associated with an HCP phenotype that does not have cutaneous involvement.

To the best of our knowledge, only two cases of HCP coexisting with SLE have been reported in the literature [9, 10]. Alioua et al. [10] reported on the coexistence of SLE and severe hepatic porphyria, and HCP was considered the most likely diagnosis. As Korkmaz [9] described, HCP was diagnosed in a patient with SLE and ankylosing spondylitis after 5 years of follow-up; therefore, they suggested that the genetic background of the autoimmune response might play a role in patients with porphyria [9]. In the reported cases, the diagnosis of HCP was made by metabolite testing, and genetic testing was lacking. In the present case, WES was first used to detect the genetic background underlying the coexistence of HCP and SLE.

SLE shows a strong genetic predisposition, and more than 100 susceptibility genes have been identified [21]. Moreover, novel genetic loci have been revealed recently [21–24]. SLC7A7 maps to chromosome 14q11.2 (11) and encodes amino acid transporter 1 (y+LAT1). Lysinuric protein intolerance (LPI), a rare autosomal recessive disease, is caused by biallelic pathogenic variants in SLC7A7. Autoimmunity and immunological abnormalities have been observed in patients with LPI, including SLE [25–27]. A significant number of genes associated with autoinflammation and autoimmunity have been implicated in monogenic lupus, including SLC7A7 [4–6]. The compound heterozygous variants in SLC7A7, namely, c.475C > T (p. Arg159Cys) and c.1001T > G (p. Leu334Arg), were detected in a patient who clinically presented with immune dysregulation in the setting of early onset SLE [28]. Li et al. [27] reported five mutations of SLC7A7: c.625+1G > A, c.235G > A, c.1085T > C, c.1387delG, and c.1215G > A, which were identified as causative mutations of SLE in 4 of 52 Chinese pediatric patients. Three compound heterozygous mutations and one homozygote mutation in SLC7A7 were revealed in these four patients. The mutation c.625+1G > A of SLC7A7 was detected in 3 of 4 patients [27]. We also detected compound heterozygous variants in SLC7A7, namely, c.625+1G > A and c.250G > A (p. V84I), in our patient, with the former consistent with the previously reported variants. Remarkably, her father also carries a SLC7A7 mutation, namely, c.625+1G > A, but has no history of SLE.

The GEO analysis revealed that CPOX expression was downregulated in the SLE patients compared with the normal controls (adj. \( P = 0.0071, \log \text{FC} = -1.0975 \)). The relationship between CPOX mutations and SLE has never been reported previously. The CPOX variant detected in the present patient may play a role in the coexistence of HCP and SLE.

The pathogenic genes of porphyria are clear and related to the function and activity of enzymes in the heme
| Case | Author reference | Sex | Age | Disease sequence | Lapsed time | ANA titer | aPL | Lupus nephritis | SLE treatment | Family history | AHPs | Genetic test |
|------|------------------|-----|-----|------------------|-------------|-----------|-----|----------------|---------------|---------------|------|-------------|
| 1    | Wolfram [29]     | F   | 30  | SLE→AIP          | 4 months    | U         | U   | U              | NR            | U             | U    |             |
| 2    | Marsden [11]     | F   | 57  | SLE→AIP          | 2 days      | U         | U   | U              | Chloroquine   | U             | U    |             |
| 3    | Passaron et al. [12] | F   | 13  | SLE→AIP          | 2 years     | U         | U   | U              | Chloroquine   | U             | U    |             |
| 4    | Filiotou et al. [8] | F   | 31  | SLE→AIP          | 1 year      | U         | U   | U              | Barbiturates  | U             | U    |             |
| 5    | Quilichini and Guerder [30] | F   | 22  | SLE→AIP          | 6 years     | U         | U   | U              | Steroids, analgesics | U   |             |
| 5    | Vittori and Desaegher [31] | F   | 22  | SLE→AIP          | 6 years     | U         | U   | U              | Steroids, analgesics | U   |             |
| 6    | Rosemarin et al. [32] | F   | 39  | SLE→AIP          | 2 years     | 1/640     | U   | Present        | Steroids, phenobarbital, and propranolol | Absent | U   |
| 7    | Allard and Scott [33] | F   | 47  | SLE→AIP          | 15 years    | NR        | aCL+| Present        | Steroids | Absent | U   |
| 8    | Andersson and Lithner [15] | F   | 37  | AIP→SLE          | NR          | NR (positive) | NR  | Present        | NR | NR | U   |
| 9    | Alioua et al. [10] | F   | 24  | SLE→HCP         | 6 months    | 1/80      | NR | NR | Steroids | Present | U   |
| 10   | Filiotou et al. [8] | F   | 43  | AIP→SLE          | 20 years    | 1/640     | NR  | Absent | Thalidomide | Present | U   |
| 11   | Korkmaz [9]      | F   | 31  | SLE→HCP          | 5 years     | 1/80      | NR | NR | Steroids, methotrexate | U   | U   |
| 12   | Bharati et al. [14] | M   | 49  | AIP→SLE          | 2 years     | 1/160     | NR | NR | Steroids, MMF | Present | DNA sequencing of intron 14 of the HMBS: IVS14+1G>T |
| 13   | Patil et al. [13] | U   | U   | SLE→AIP          | NR          | NR        | NR | NR | Steroids | U | U   |
| 14   | Esteve-Valverde et al. [7] | M   | 51  | SLE→AIP          | 10 days     | 1/1280    | IgG-ab2GPI+ | Absent | Steroids, HCQ, and azathioprine | Absent | U   |
| 15   | Present case (2020) | F   | 30  | SLE→HCP         | 6 years     | 1/640 (SLE) | 1/160 (HCP) | Negative | Absent | Steroids, HCQ | Absent | WES: a splicing mutation of CPOX: c.700+2 T>C (intron 2) |

Modified from Esteve-Valverde et al. [7]. AHPs: acute hepatic porphyrias; AIP: acute intermittent porphyria; ANA: antinuclear antibodies; SLE: systemic lupus erythematosus; HCP: hereditary coproporphyria; aPL: antiphospholipid antibodies; aCL: anticardiolipin; IgG-ab2GPI: IgG antiβ2-GPI; MMF: mycophenolate mofetil; HCQ: hydroxychloroquine; HMBS: hydroxymethylbilane synthase gene; WES: whole exome sequencing; CPOX: coproporphyrinogen III oxidase gene; NR: not referred; U: unknown. *Same patient.
biosynthetic pathway. The proband was diagnosed with HCP due to a splicing mutation of CPOX (c.700+2 T > C). The same SLC7A7 mutation (c.625+1 G > A) was detected both in the proband and her father, although only the proband presented with SLE. We suggest that the SLC7A7 mutation is related to the immune dysregulation of SLE and that the CPOX mutation promotes this process. The mentioned variants have been submitted to the ClinVar database. Further research needs to be conducted to investigate the mechanism underlying the coexistence of HCP and SLE.

5. Limitations

In this patient, the positive UPG and PBG and increased FEP revealed the presence of AHP, and the diagnosis of HCP was identified by a CPOX mutation analysis. However, neither stool metabolite testing nor CPOX enzyme activity detection was performed to further confirm HCP. In addition, we did not assess protein expression by reverse transcription assay or immunohistochemistry.

6. Conclusion

We reported a rare case of HCP coexisting with SLE and described the diagnosis difficulties. This is the first reported case of SLE coexisting with HCP in China. We reported a novel splicing mutation of CPOX, i.e., c.700+2 T > C (intron 2), as well as compound heterozygous mutations of SLC7A7. Urine testing of porphyrin precursors is an easy and efficient technique, while genetic testing is still the gold standard for the subtype diagnosis of porphyria. The simultaneous mutation of CPOX and SLC7A7 may explain the etiopathogenetic connections of HCP and SLE. A better understanding of the pathogenesis could facilitate the prediction and prevention of acute porphyria attacks.

Abbreviations

ACMG: American College of Medical Genetics
AHPs: Acute hepatic porphyrias
AIP: Acute intermittent porphyria
ALADP: Aminolevulinic acid dehydratase deficient porphyria
ANA: Antinuclear antibodies
ClinVar: Clinically relevant variants
CPOX: Coproporphyrinogen III oxidase
CPOX: Coproporphyrinogen III oxidase gene
DEGs: Differentially expressed genes
ds-DNA: Double-stranded DNA
ESR: Erythrocyte sedimentation rate
FEP: Free erythrocyte protoporphyrin
GEO: Gene expression omnibus
HCP: Hereditary coproporphyria
HCQ: Hydroxychloroquine
HMBS: Hydroxymethylbilane synthase
HMBS: Hydroxymethylbilane synthase gene
ITP: Immune thrombocytopenia
MMF: Mycophenolate moftil
PBG: Porphobilinogen
REVEL: Rare exome variant ensemble learner
SLE: Systemic lupus erythematosus
SLC7A7: Solute carrier family 7 member 7 gene
UPG: Uroporphyrinogen
VP: Variegate porphyria
WES: Whole exome sequences.

Data Availability

All data generated or analyzed during this study are included in the published article. The raw data is available upon request from the corresponding author.

Ethical Approval

All procedures followed were in accordance with the ethical standards of the responsible institutional committee on human experimentation and with the Helsinki Declaration of 1975 (revised in 2000). The study protocol was approved by the Ethics Committee of the Institutional Review Board at Peking Union Medical College Hospital (PUMCH).

Consent

A written consent form, stating acceptance of genetic testing, was signed by the patient and her family members. Written informed consent was obtained from the patient’s family.

Conflicts of Interest

The authors declare that they have no competing interests.

Authors’ Contributions

Anlei Liu and Lingli Zhou were responsible for the substantial contributions to conception, design, and writing. Yi Li, Huadong Zhu, and Jing Yang all had drafted the article or revised it. Anlei Liu and Lingli Zhou contributed equally to this work.

Acknowledgments

This work was supported by the Cardiovascular Multidisciplinary Integrated Research Fund (CIMF-Z-2016-23-2001-04).

References

[1] U. Stolzel, M. O. Doss, and D. Schuppan, “Clinical guide and update on porphyrias,” Gastroenterology, vol. 157, no. 2, pp. 365–381.e4, 2019.
[2] S. Gupta and M. J. Kaplan, “Bite of the wolf: innate immune responses propagate autoimmunity in lupus,” The Journal of Clinical Investigation, vol. 131, no. 3, 2021.
[3] S. G. Guerra, T. J. Vyse, and D. S. Cunningham Graham, “The genetics of lupus: a functional perspective,” Arthritis Research & Therapy, vol. 14, no. 3, p. 211, 2012.
[4] J. M. Alperin, L. Ortiz-Fernandez, and A. H. Sawalha, “Monogenic lupus: a developing paradigm of disease,” Frontiers in Immunology, vol. 9, p. 2496, 2018.
[5] S. Dasdemir, M. Yildiz, D. Celebi, et al., “Genetic screening of early-onset patients with systemic lupus erythematosus by a targeted next-generation sequencing gene panel,” Lupus, vol. 31, no. 3, pp. 330–337, 2022.

[6] I. Tirosch, S. Spielman, O. Barel et al., “Whole exome sequencing in childhood-onset lupus frequently detects single gene etiologies,” Pediatric Rheumatology Online Journal, vol. 17, no. 1, p. 52, 2019.

[7] E. Esteve-Valverde, A. Tapiz-Reula, D. Ruiz, and J. Alijotas-Reig, “Systemic lupus erythematosus and hydroxychloroquine-related acute intermittent porphyria,” Rheumatology International, vol. 40, no. 5, pp. 777–783, 2020.

[8] A. Filiotou, G. Vaiopoulos, V. Capsimali, N. Stavrianeas, and A. Kaloterakis, “Acute intermittent porphyria and systemic lupus erythematosus: report of a case and review of the literature,” Lupus, vol. 11, no. 3, pp. 190–192, 2002.

[9] C. Korkmaz, “Delayed diagnosis of porphyria based on manifestations of systemic lupus erythematosus and ankylosing spondylitis,” Journal of Nephropathy, vol. 19, no. 4, pp. 535–539, 2006.

[10] C. Alioua, A. Patel, and A. A. Bakir, “Coexistence of systemic lupus erythematosus and severe hepatic porphyria,” Nephrology, Dialysis, Transplantation, vol. 14, no. 12, pp. 2944–2946, 1999.

[11] C. W. Marsden, “Porphyria during chloroquine therapy,” The British Journal of Dermatology, vol. 71, no. 6, pp. 219–222, 1969.

[12] H. N. Passaron, J. H. Lloveras, and E. Vazquez, “Exacerbated chronic lupus erythematosus and acute porphyria,” Archivos Argentinos de Dermatologia, vol. 12, pp. 299–303, 1962.

[13] A. D. Patil, N. D. Karnik, M. Y. Nadkar, V. A. Gupta, K. Muralidhara, and S. Passidhi, “Guillain Barré syndrome, systemic lupus erythematosus and acute intermittent porphyria - a deadly trio,” The Journal of the Association of Physicians of India, vol. 63, no. 11, pp. 60–63, 2002.

[14] A. Bharati, E. Kleyne, G. A. Wong, N. Leonard, and C. M. King, “A spectrum of lupus erythematosus from verrucous to systemic, coexisting with two types of porphyria,” Journal of the European Academy of Dermatology and Venereology, vol. 21, no. 7, pp. 1009-1010, 2007.

[15] C. Andersson and F. Lithner, “Hypertension and renal disease in patients with acute intermittent porphyria,” Journal of Internal Medicine, vol. 236, no. 2, pp. 169–175, 1994.

[16] http://www.drugs-porphyria.org/.

[17] D. Lambie, C. Florkowski, C. Sies, A. Raizis, W. K. Siu, and C. Towns, “A case of hereditary coproporphyria with posterior reversible encephalopathy and novel coproporphyrinogen oxidase gene mutation c.863T>G (p.Leu288Trp),” Annals of Clinical Biochemistry, vol. 55, no. 5, pp. 616–619, 2018.

[18] Z. Karim, S. Lyoumi, G. Nicolas, J. C. Deybach, L. Gouya, and H. Puy, “Porphyrias: a 2015 update,” Clinics and Research in Hepatology and Gastroenterology, vol. 39, no. 4, pp. 412–425, 2015.

[19] B. Chen, S. Whatley, M. Badminton et al., “International porphyria molecular diagnostic collaborative: an evidence-based database of verified pathogenic and benign variants for the porphyrias,” Genetics in Medicine, vol. 21, no. 11, pp. 2605–2613, 2019.

[20] T. Fukui, E. Akasaka, D. Rokunohe et al., “Analysis of the mechanism underlying a mild phenotype of hereditary coproporphyria due to a homozygous missense mutation in the transcription initiation codon of the coproporphyrinogen III oxidase gene,” Journal of Dermatological Science, vol. 100, no. 2, pp. 156–159, 2020.

[21] X. Yin, K. Kim, H. Suetsugu et al., “Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for systemic lupus erythematosus,” Annals of the Rheumatic Diseases, vol. 80, no. 5, pp. 632–640, 2021.

[22] Y. Y. Qi, Y. F. Zhao, Y. L. Zhai et al., “SCUBE3 is likely a susceptibility gene for systemic lupus erythematosus for Chinese populations,” Journal of Immunology Research, vol. 2020, Article ID 8897936, 7 pages, 2020.

[23] G. Hou, I. T. W. Harley, X. Lu et al., “SLE non-coding genetic risk variant determines the epigenetic dysfunction of an immune cell specific enhancer that controls disease-critical microRNA expression,” Nature Communications, vol. 12, no. 1, p. 135, 2021.

[24] Q. Song, Y. Lei, L. Shao et al., “Genome-wide association study on Northern Chinese identifies KLF2, DOT1L and STAB2 associated with systemic lupus erythematosus,” Rheumatology (Oxford), vol. 60, no. 9, pp. 4407–4417, 2021.

[25] H. Parsons, F. Snyder, T. Bowen, J. Klassen, and A. Pinto, “Immune complex disease consistent with systemic lupus erythematosus in a patient with lysinuric protein intolerance,” Journal of Inherited Metabolic Disease, vol. 19, no. 5, pp. 627–634, 1996.

[26] T. Kamoda, Y. Nagai, M. Shigeta et al., “Lysinuric protein intolerance and systemic lupus erythematosus,” European Journal of Pediatrics, vol. 157, no. 2, pp. 130–131, 1998.

[27] G. Li, H. Liu, Y. Li et al., “Genetic heterogeneity in Chinese children with systemic lupus erythematosus,” Clinical and Experimental Rheumatology, vol. 39, no. 1, pp. 214–222, 2021.

[28] J. L. Contreras, M. A. Ladino, K. Aránguiz et al., “Immune dysregulation mimicking systemic lupus erythematosus in a patient with lysinuric protein intolerance: case report and review of the literature,” Frontiers in Pediatrics, vol. 9, article 673957, 2021.

[29] S. Wolfram, “Colic caused by porphyria; symptomatology of the acute erythematodes,” Hautarzt, vol. 3, no. 7, pp. 298–300, 1952.

[30] R. Quilichini and A. Guerder, “Systemic lupus erythematosus and acute intermittent porphyria,” The Lancet, vol. 2, no. 1527, p. 135, 2021.

[31] F. Vittori and J. L. Desaegher, “Systemic lupus erythematosus and intermittent acute porphyria. Association or coincidence?,” La Semaine des Hôpitaux, vol. 53, no. 25–28, pp. 1542–1548, 1977.

[32] J. I. Rosemarin, E. J. Nigro, R. D. Levere, and B. R. Mascarenhas, “Systemic lupus erythematosus and acute intermittent porphyria: coincidence or association?,” Arthritis and Rheumatism, vol. 25, no. 9, pp. 1134–1137, 1982.

[33] S. A. Allard and J. T. Scott, “Systemic lupus erythematosus and acute intermittent porphyria,” British Journal of Rheumatology, vol. 28, no. 3, pp. 254–256, 1989.